Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the safety and efficacy of the bivalent COVID-19 vaccines in children under age 5. Although the U.S. Food and Drug Administration and Centers for Disease Control and Prevention have given early use authorization for the bivalent COVID-19 vaccine, children under 5 are still only eligible for the monovalent vaccine.

Partnering with Pfizer/BioNTech, the Pediatric Clinical Research Center at Rutgers Robert Wood Johnson Medical School will begin to study the bivalent vaccine in children less than 5 years old. The trial will include a substudy of children under 2 who have never received a COVID-19 vaccine and a substudy for children under 5 who have received doses of COVID vaccines. To read the full story.